138 patents currently held
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
76 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
72
Ending by 2030
Dec 2026
Next term end
75
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2028 · High confidence
Also notable
Ends Dec 2026 · High confidence
Also notable
Ends May 2029 · Medium confidence
Also notable
Ends Nov 2031 · High confidence
Also notable
Ends Dec 2027 · High confidence
Also notable
Ends Feb 2035 · High confidence
Also notable
Ends Aug 2030 · High confidence
Also notable
Ends Aug 2029 · High confidence
Chemically Modified Small Molecules
US 7,786,133
The most cited patent in this portfolio, cited by 122 later US patents, top 5% of utility patents granted in 2010 in our data. Protection runs to 2028.
Multi-Arm Polymer Prodrugs
US 7,744,861
Cited by 119 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2026.
Oligomer-Opioid Agonist Conjugates
US 8,173,666
Cited by 52 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Conjugates of an IL-2 Moiety and a Polymer
US 9,861,705
Cited by 39 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Polymer Derivatives Having Particular Atom Arrangements
US 7,887,789
Cited by 66 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
IL-2RBETA-SELECTIVE Agonists in Combination with an ANTI-CTLA-4 Antibody or an ANTI-PD-1 Antibody
US 10,786,552
Cited by 11 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Conjugates Having a Degradable Linkage and Polymeric Reagents Useful in Preparing Such Conjugates
US 8,252,275
The largest patent family in this portfolio, 11 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Multi-Arm Polymeric Alkanoate Conjugates
US 8,962,566
The largest patent family in this portfolio, 7 related applications, renewed at every maintenance window due so far. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Oct 2032 · High confidence
Cited by 116 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
now held by Stamford Devices Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 13 to 18, 2026 · next Dec 13
- 4 fees due Jan 21 to 28, 2027 · next Jan 21
- 6 fees due Feb 4 to 18, 2027 · next Feb 4
- 2 fees due Mar 5 to 10, 2027 · next Mar 5
- 1 fee due Apr 8, 2027The maintenance fee for Oligomer-Containing Benzamide-Based Compounds (US 10,434,181) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
- 5 fees due May 3 to 26, 2027 · next May 3
- 3 fees due Jun 1 to 24, 2027 · next Jun 1
- 10 fees due Jul 5 to 12, 2027 · next Jul 5
- 1 fee due Aug 23, 2027The maintenance fee for Oligomer-Containing Substituted Aromatic Triazine Compounds (US 9,266,845) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Method of Making Releasable Polymeric Reagents (US 11,932,726) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 1 fee due Oct 26, 2027The maintenance fee for Acid Salt Forms of Polymer-Drug Conjugates and Alkoxylation Methods (US 9,320,808) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
- 1 fee due Nov 19, 2027The maintenance fee for Combination-Based Treatment Method (US 10,653,689) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.
Recent changes
- 7 terms have ended since Aug 23, 2026
- Oct 21 US 8,865,149 Polymeric reagents comprising a ketone or a related functional group · lapsed on the fee record
- Oct 11 US 11,464,788 Oligomer-Corticosteroid Conjugates · lapsed on the fee record
- Oct 9 US 10,092,656 Protease Inhibitors Having Enhanced Features · lapsed on the fee record
- Oct 7 US 8,853,247 Oligomer-Nitroimidazole Anti-Infective Conjugates · lapsed on the fee record
- Sep 25 US 10,081,602 Opioid Agonists and Uses Thereof · lapsed on the fee record
- Sep 16 US 8,835,599 Segmented Degradable Polymers and Conjugates Made Therefrom · lapsed on the fee record
- Sep 9 US 8,829,043 Oligomer-Cannabinoid Conjugates · lapsed on the fee record
What they patent
The largest of its 75 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,744,861 | Multi-Arm Polymer Prodrugs In force · High confidence | In force | High confidence | |
| US 7,608,663 | Method of Preparing Propionic Acid-Terminated Polymers In force · High confidence | In force | High confidence | |
| US 10,232,042 | Conjugates of an Anti-Tnf-Alpha Antibody In force · Medium confidence | In force | Medium confidence | |
| US 9,636,412 | Conjugates of an Anti-Tnf-Alpha Antibody In force · High confidence | In force | High confidence | |
| US 7,872,082 | Method for Preparing Polymer Maleimides In force · High confidence | In force | High confidence | |
| US 8,937,180 | Method for Preparing a Polymer Conjugate In force · Medium confidence | In force | Medium confidence | |
| US 7,887,789 | Polymer Derivatives Having Particular Atom Arrangements In force · High confidence | In force | High confidence | |
| US 8,440,687 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 8,569,343 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 8,575,196 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 138: 13 patents in force now held by others · 292 patents ended · 7 applications pending · 170 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.